[Photo by Karolina Grabowska via Pexels]
In 1986, the ulcer drug Tagamet from Smith, Kline and French (now GSK) emerged as the first blockbusters, generating more than $1 billion in annual revenue. Fast-forward to 2021, and the COVID-19 vaccine from Pfizer and BioNTech generated close to $60 billion in cumulative revenue. That same year, AbbVie’s Humira (adalimumab) eclipsed $20 billion in sales for the first time. Last year, we profiled 50 blockbusters that each generated multiple billions of dollars in 2021.Here, we survey 25 potential blockbusters that have either recently won regulatory approval are poised to do so in the near future:
Drug name Brand name Developer(s) Description 1. Adagrasib Krazati Mirati Therapeutics The KRASG12C inhibitor adagrasib won Breakthrough Therapy Designation for patients with advanced non-small cell lung cancer (NSCLC) with the KRASG12C mutation in 2021. In e…